Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR）
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Observational; No Interventions were given..
- Who it may be relevant to
- Registry conditions: Infective Endocarditis. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prognosis of Patients With Infective Endocarditis and Risk Stratification Value of Biomarkers (ENDEAVOR): a National Multi-center, Retrospective-prospective, Cohort Study Initiated by the Investigators
Overview
In this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.
Detailed description
Infective endocarditis is an inflammation of the inner lining of the heart valves or ventricular walls caused by direct infection of the heart by bacteria, fungi and other microorganisms via the bloodstream route. At present, the clinical diagnosis of IE is mainly based on a combination of typical symptoms, imaging and blood culture, etc. Finding more sensitive means and more accurate indicators for early detection of IE flora distribution characteristics is of great significance for the prevention and targeted treatment of IE. Therefore, in this study, by establishing a clinical cohort of infective endocarditis, we observed the natural prognosis and influencing factors in the process of disease development and regression; we used multi-omics technology to understand the prognostic value of its biomarkers, and provided new ideas and evidence for the pathogenesis, clinical diagnosis and treatment of IE.
Interventions
- Other Observational; No Interventions were given.
Observational; No Interventions were given.
Primary outcome measures
- Change in the incidence of MACCE [Time frame: 1, 3, 6 months and 1, 2, 3, 5 years after enrollment.]
Secondary outcome measures (6)
- Incidence of adverse thrombus complications [Time frame: 5 years after the enrollment.]
- Change in the incidence of infection recurrence [Time frame: 1, 3, 6 months and 1, 2, 3, 5 years after enrollment.]
- Change in the incidence of myocardial infarction [Time frame: 1, 3, 6 months and 1, 2, 3, 5 years after enrollment.]
- Change in the incidence of stroke [Time frame: 1, 3, 6 months and 1, 2, 3, 5 years after enrollment.]
- Change in the incidence of vessel revascularization [Time frame: 1, 3, 6 months and 1, 2, 3, 5 years after enrollment.]
- Change in the incidence of all-cause death [Time frame: 1, 3, 6 months and 1, 2, 3, 5 years after enrollment.]
Eligibility criteria
Inclusion criteria
- Patients with clinically confirmed infective endocarditis
Exclusion criteria
- Patients refuse to sign informed consent form
- Patients who combined with serious systemic diseases, cannot tolerate the acquisition of biological samples
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- First Affiliated Hospital of Xian Jiantong University — Xi'an
Identifiers
NCT: NCT05965362 · XJTU1AF2023LSK-151